Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States. This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations. Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants. Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence -highlights historical studies of dietary trials designed to reduce CHD -covers tests of HMG CoA reductase inhibitors for patients with and without CHD -illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking -explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors -reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol -and more! Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines.

Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States. This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations. Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants. Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence highlights historical studies of dietary trials designed to reduce CHD covers tests of HMG CoA reductase inhibitors for patients with and without CHD illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol and more! Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines.

This new edition is an integral source of information on Atherosclerosis. It covers topics such as newer coronary risk factors, high-density lipoprotein metabolism, lipid-lowering drugs, endothelium and thrombosis in atherogenesis, and contributing risk factors. With over 500 exceptional photographs, diagrams, and charts, each chapter illustrates an important facet of diagnosing and treating this common and often fatal disease.

In this updated fifth edition of the Atlas of Atherosclerosis and Metabolic Syndrome (formerly the Atlas of Atherosclerosis), the editors have compiled a comprehensive update on the field of atherosclerosis. This four-color atlas includes detailed legends and extensive reference listings for hundreds of illustrations, algorithms, schematics, and images. This new edition focuses more closely on metabolic syndrome, as well as comprehensively covering many other topics including diabetes and vascular risk, obesity management, dietary concerns, drug treatment, gender and ethnicity differences, and many others. The striking, four-color format combined with the breadth of information it contains make this book an invaluable resource for physicians, cardiologists, and all professionals involved in the study and treatment of atherosclerosis.